ClinicalTrials.gg
CompletedNCT04774627Updated Sep 23, 2021

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

An observational study in Cancer, sponsored by University Hospital, Caen. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2021-09-23.

Sponsored by University Hospital, Caen · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
200
Sex
All
01

Study summary

Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious adverse events such as pancytopenia. Today, data about pancytopenia are scarce.

The objective was to investigate reports of pancytopenia adverse events related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib and pamiparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.

Read the detailed description

Here, investigators use the World Health Organization's (WHO) database of individual safety case reports, to identify cases of pancytopenia related to PARPi.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 200 is close to the median of 200 across 2,641 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University Hospital, Caen is the lead sponsor of 514 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cancer patients treated with PARPi and experiencing pancytopenia.

Eligibility criteria

Inclusion Criteria:

  • case reported in the World Health Organization (WHO) database (VigiBase) of individual safety case reports at the time of the extraction,
  • patients treated with at least 1 PARPi (with ATC classification system): olaparib (ATC L01XX46), niraparib (ATC L01XX54), rucaparib (ATC L01XX55), talazoparib (ATC L01XX60), veliparib (none) and pamiparib (none).

Exclusion Criteria: chronology not compatible between the PARPi and adverse event.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
200 participants (actual)
Patient registry
No

Interventions

  • All patients treated at least with 1 PARPi

    Also known as: olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib

This study also gives Olaparib, Niraparib, Rucaparib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Pancytopenia reports related to PARPi.

    Identification of the pancytopenia adverse event related to PARP inhibitors reported in the World Health Organization's (WHO) database of individual safety case reports.

    Time frame: From inception to Feb, 2021

Secondary outcomes

  1. Description of the latency period since first PARPi exposure.

    Time frame: From inception to Feb, 2021

  2. Description of the fatality rate.

    Time frame: From inception to Feb, 2021

  3. Description of patients who experienced co-reported adverse events

    Time frame: From inception to Feb, 2021

07

Study locations

1 site
  • Alexandre Joachim
    Caen, Basse Normandie 14000, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Feb 2021, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2021
First posted
Mar 1, 2021
StartActual
Feb 7, 2021
Primary completionActual
Feb 27, 2021
CompletionActual
Mar 24, 2021
Last update
Sep 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04774627
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Feb 7, 2021
Primary completion
Feb 27, 2021
Completion
Mar 24, 2021
Last update
Sep 23, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion